PolyNovo Limited (ASX:PNV)

Australia flag Australia · Delayed Price · Currency is AUD
1.310
-0.030 (-2.24%)
Jun 6, 2025, 4:10 PM AEST
-39.63%
Market Cap 925.73M
Revenue (ttm) 115.58M
Net Income (ttm) 5.91M
Shares Out 690.84M
EPS (ttm) 0.01
PE Ratio 159.56
Forward PE 89.93
Dividend n/a
Ex-Dividend Date n/a
Volume 1,082,756
Average Volume 2,284,298
Open 1.360
Previous Close 1.340
Day's Range 1.297 - 1.360
52-Week Range 0.930 - 2.780
Beta 1.56
RSI 52.44
Earnings Date May 23, 2025

About PolyNovo

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MT... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1998
Employees 254
Stock Exchange Australian Securities Exchange
Ticker Symbol PNV
Full Company Profile

Financial Performance

Financial Statements

News

PolyNovo chief executive steps down after dispute with chairman

The burns treatment biotech has had a difficult year and now Swami Raote is leaving after a slump in the company’s share price and a brawl with the board.

3 months ago - The Australian Financial Review

David Williams says he makes no apologies for ‘aggressive’ style

The outspoken investment banker is the chairman of PolyNovo. The burns treatment company’s chief executive is leaving after a falling out with the board.

3 months ago - The Australian Financial Review

Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and ...

Polynovo Ltd (CALZF) (Q4 2024) Earnings Call Transcript Highlights: Record Revenue and Strategic Growth

10 months ago - GuruFocus